Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 2/2015

01-04-2015 | EDITORIAL

Some Like it Hot: Cardioprotective Effect of Curcumin in Chronic Kidney Disease

Editorial to: “Cardioprotection by Curcumin Post-Treatment in Rats with Established Chronic Kidney Disease” by S. Hernandez-Resendiz et al.

Author: Elena N. Dedkova

Published in: Cardiovascular Drugs and Therapy | Issue 2/2015

Login to get access

Excerpt

Chronic kidney disease (CKD) is a progressive loss of kidney structure (i.e., proteinuria, abnormal urinary sediment, abnormalities on imaging studies) and function (i.e., glomerular filtration rate (GFR) <60 mL/min per 1.73 m2) over a period of 3 months or longer which leads to accumulation of water, waste, and toxic substances in the body that are normally excreted by the kidney [1]. The presence of CKD confers a markedly increased risk of cardiovascular disease, and in fact patients with CKD die primarily from cardiovascular complications rather than from end-stage renal failure [2, 3]. The kidney plays a central role in electrolyte balance, volume, and blood pressure regulation; all of these parameters have a significant impact on cardiovascular health [4]. If the kidneys fail to work properly, fluid builds up quickly in the lungs and heart leading to hypervolemia. This increases the workload of the heart and could lead to chronic heart failure due to volume-overload with increased central venous pressure and low systematic arterial pressure [5]. This in turn reduces net renal perfusion pressure, further reducing renal function and stimulating many neurohumoral factors such as the renin–angiotensin–aldosterone system (RAAS), the sympathetic nervous system, including the adrenals, and the arginine–vasopressin system, to maintain renal blood supply [6]. In addition, the metabolic disturbances in CKD accelerate the atherosclerotic process causing vascular calcification and stiffness leading to pressure overload. Histopathological studies indicate that capillary density is reduced in the hypertrophied myocardium, and pronounced interstitial fibrosis is a dominant feature of CKD-associated structural myocardial remodeling [5]. Furthermore, higher rates of arrhythmias and sudden death are observed in CKD due to shifts in electrolyte balance and myocardial substrate. …
Literature
2.
go back to reference Selvarajah S, Uiterwaal CS, Haniff J, van der Graaf Y, Visseren FL, Bots ML, et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Investig. 2013;43:198–207.CrossRef Selvarajah S, Uiterwaal CS, Haniff J, van der Graaf Y, Visseren FL, Bots ML, et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Investig. 2013;43:198–207.CrossRef
3.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
4.
go back to reference McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens. 2004;13:591–600.CrossRefPubMed McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist’s perspective. Curr Opin Nephrol Hypertens. 2004;13:591–600.CrossRefPubMed
5.
go back to reference Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.CrossRefPubMed Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572–86.CrossRefPubMed
7.
go back to reference Hernandez-Resendiz S, Correa F, Garcia-Nino WR, Buelna-Chontal M, Roldan FJ, Ramirez-Camacho I, Delgado-Toral C, Carbo R, Pedraza-Chaverri J, Tapia E, Zazueta C. Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease. Cardiovasc Drugs Ther. 2015;29: this issue. Hernandez-Resendiz S, Correa F, Garcia-Nino WR, Buelna-Chontal M, Roldan FJ, Ramirez-Camacho I, Delgado-Toral C, Carbo R, Pedraza-Chaverri J, Tapia E, Zazueta C. Cardioprotection by curcumin post-treatment in rats with established chronic kidney disease. Cardiovasc Drugs Ther. 2015;29: this issue.
8.
go back to reference Correa F, Buelna-Chontal M, Hernández-Reséndiz S, García-Niño WR, Roldán FJ, Soto V, et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free Radic Biol Med. 2013;61:119–29.CrossRefPubMed Correa F, Buelna-Chontal M, Hernández-Reséndiz S, García-Niño WR, Roldán FJ, Soto V, et al. Curcumin maintains cardiac and mitochondrial function in chronic kidney disease. Free Radic Biol Med. 2013;61:119–29.CrossRefPubMed
9.
go back to reference Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–55.CrossRefPubMedCentralPubMed Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–55.CrossRefPubMedCentralPubMed
10.
go back to reference Akbik D, Ghadiri M, Chrzanowski W, Rohanizadeh R. Curcumin as a wound healing agent. Life Sci. 2014;116:1–7.CrossRefPubMed Akbik D, Ghadiri M, Chrzanowski W, Rohanizadeh R. Curcumin as a wound healing agent. Life Sci. 2014;116:1–7.CrossRefPubMed
11.
go back to reference Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75:787–809.CrossRefPubMed Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol. 2008;75:787–809.CrossRefPubMed
12.
go back to reference Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32:1053–64.CrossRefPubMed Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32:1053–64.CrossRefPubMed
13.
go back to reference Tapia E, Soto V, Ortiz-Vega KM, Zarco-Marquez G, Molina-Jijon E, Cristobal-Garcia M, et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev. 2012;2012:269039.CrossRefPubMedCentralPubMed Tapia E, Soto V, Ortiz-Vega KM, Zarco-Marquez G, Molina-Jijon E, Cristobal-Garcia M, et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid Med Cell Longev. 2012;2012:269039.CrossRefPubMedCentralPubMed
14.
go back to reference Dyer JL, Khan SZ, Bilmen JG, Hawtin SR, Wheatley M, Javed MU, et al. Curcumin: a new cell-permeant inhibitor of the inositol 1,4,5-trisphosphate receptor. Cell Calcium. 2002;31:45–52.CrossRefPubMed Dyer JL, Khan SZ, Bilmen JG, Hawtin SR, Wheatley M, Javed MU, et al. Curcumin: a new cell-permeant inhibitor of the inositol 1,4,5-trisphosphate receptor. Cell Calcium. 2002;31:45–52.CrossRefPubMed
15.
go back to reference Yamda J, Ohkusa T, Nao T, Ueyama T, Yano M, Kobayashi S, et al. Up-regulation of inositol 1,4,5 trisphosphate receptor expression in atrial tissue in patients with chronic atrial fibrillation. J Am Coll Cardiol. 2001;37:1111–9.CrossRefPubMed Yamda J, Ohkusa T, Nao T, Ueyama T, Yano M, Kobayashi S, et al. Up-regulation of inositol 1,4,5 trisphosphate receptor expression in atrial tissue in patients with chronic atrial fibrillation. J Am Coll Cardiol. 2001;37:1111–9.CrossRefPubMed
16.
go back to reference Arantes LA, Aguiar CJ, Amaya MJ, Figueiro NC, Andrade LM, Rocha-Resende C, et al. Nuclear inositol 1,4,5-trisphosphate is a necessary and conserved signal for the induction of both pathological and physiological cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2012;53:475–86.CrossRefPubMed Arantes LA, Aguiar CJ, Amaya MJ, Figueiro NC, Andrade LM, Rocha-Resende C, et al. Nuclear inositol 1,4,5-trisphosphate is a necessary and conserved signal for the induction of both pathological and physiological cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2012;53:475–86.CrossRefPubMed
17.
go back to reference Yoo SH. Chromogranins and inositol 1,4,5-trisphosphate-dependent Ca(2+)-signaling in cardiomyopathy and heart failure. Curr Med Chem. 2012;19:4068–73.CrossRefPubMed Yoo SH. Chromogranins and inositol 1,4,5-trisphosphate-dependent Ca(2+)-signaling in cardiomyopathy and heart failure. Curr Med Chem. 2012;19:4068–73.CrossRefPubMed
18.
go back to reference Ghosh SS, Salloum FN, Abbate A, Krieg R, Sica DA, Gehr TW, et al. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol. 2010;299:H975–84.CrossRefPubMedCentralPubMed Ghosh SS, Salloum FN, Abbate A, Krieg R, Sica DA, Gehr TW, et al. Curcumin prevents cardiac remodeling secondary to chronic renal failure through deactivation of hypertrophic signaling in rats. Am J Physiol Heart Circ Physiol. 2010;299:H975–84.CrossRefPubMedCentralPubMed
19.
go back to reference Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J Mol Cell Cardiol. 2015;79:1–12.CrossRefPubMed Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, et al. Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-kappaB both in vitro and in vivo. J Mol Cell Cardiol. 2015;79:1–12.CrossRefPubMed
20.
go back to reference Ma Q. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol. 2013;53:401–26.CrossRef Ma Q. Role of nrf2 in oxidative stress and toxicity. Ann Rev Pharmacol Toxicol. 2013;53:401–26.CrossRef
Metadata
Title
Some Like it Hot: Cardioprotective Effect of Curcumin in Chronic Kidney Disease
Editorial to: “Cardioprotection by Curcumin Post-Treatment in Rats with Established Chronic Kidney Disease” by S. Hernandez-Resendiz et al.
Author
Elena N. Dedkova
Publication date
01-04-2015
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2015
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-015-6586-5

Other articles of this Issue 2/2015

Cardiovascular Drugs and Therapy 2/2015 Go to the issue